Kodiak Sciences Inc. $KOD Shares Purchased by Vanguard Personalized Indexing Management LLC

Vanguard Personalized Indexing Management LLC lifted its holdings in Kodiak Sciences Inc. (NASDAQ:KOD) by 21.7% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 15,070 shares of the company’s stock after purchasing an additional 2,691 shares during the period. Vanguard Personalized Indexing Management LLC’s holdings in Kodiak Sciences were worth $56,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Acadian Asset Management LLC increased its position in shares of Kodiak Sciences by 27.0% in the first quarter. Acadian Asset Management LLC now owns 1,946,134 shares of the company’s stock worth $5,454,000 after acquiring an additional 413,821 shares in the last quarter. Jacobs Levy Equity Management Inc. boosted its holdings in shares of Kodiak Sciences by 90.1% during the first quarter. Jacobs Levy Equity Management Inc. now owns 685,198 shares of the company’s stock worth $1,922,000 after purchasing an additional 324,722 shares during the period. Nuveen LLC acquired a new stake in shares of Kodiak Sciences during the first quarter worth approximately $392,000. Adage Capital Partners GP L.L.C. boosted its holdings in shares of Kodiak Sciences by 16.3% during the first quarter. Adage Capital Partners GP L.L.C. now owns 1,325,707 shares of the company’s stock worth $3,719,000 after purchasing an additional 186,180 shares during the period. Finally, XTX Topco Ltd acquired a new stake in shares of Kodiak Sciences during the first quarter worth approximately $126,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

Analyst Ratings Changes

Several analysts recently commented on KOD shares. HC Wainwright raised their price target on shares of Kodiak Sciences from $3.00 to $5.00 and gave the stock a “neutral” rating in a report on Monday, August 18th. JPMorgan Chase & Co. upgraded shares of Kodiak Sciences from a “neutral” rating to an “overweight” rating and raised their price target for the stock from $15.00 to $24.00 in a report on Friday. Chardan Capital restated a “neutral” rating and set a $14.00 price target on shares of Kodiak Sciences in a report on Monday, October 6th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Kodiak Sciences in a research note on Wednesday, October 8th. Finally, Barclays upgraded shares of Kodiak Sciences from an “underweight” rating to an “equal weight” rating and lifted their target price for the company from $7.00 to $17.00 in a research note on Thursday, September 25th. Three research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Kodiak Sciences currently has a consensus rating of “Hold” and a consensus target price of $19.17.

Kodiak Sciences Stock Up 0.7%

Kodiak Sciences stock opened at $18.83 on Tuesday. Kodiak Sciences Inc. has a 12-month low of $1.92 and a 12-month high of $20.13. The business’s 50-day moving average price is $12.50 and its two-hundred day moving average price is $7.47. The stock has a market cap of $994.60 million, a PE ratio of -4.96 and a beta of 2.67.

Kodiak Sciences (NASDAQ:KOD) last released its quarterly earnings results on Wednesday, August 13th. The company reported ($1.03) earnings per share for the quarter, missing the consensus estimate of ($1.01) by ($0.02). As a group, analysts expect that Kodiak Sciences Inc. will post -3.45 earnings per share for the current year.

About Kodiak Sciences

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.